GenSight Biologics has successfully raised nearly €2 million from existing shareholders Invus and Alumni Capital to advance its gene therapy programs.
Amount Raised
€2 Million
Round Type
Funding Round
ParisBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
GenSight Biologics has announced the completion of a EUR 1,999,998 fundraising subscribed by existing shareholders, Invus and Alumni Capital. This fundraising follows previous rounds and aims to bolster the development of the company's gene therapies. CEO Laurence Rodriguez highlighted the confidence this investment brings to their strategic progress. The company focuses on therapies for retinal neurodegenerative diseases.
Quick answer
GenSight Biologics raised €2 Million in a Funding Round round, dated November 10, 2025. Investors: Alumni Capital and Invus. GenSight Biologics is based in Paris, Ile-de-France, France.
- How much did GenSight Biologics raise?
- GenSight Biologics raised €2 Million in a Funding Round round on November 10, 2025.
- Who invested in GenSight Biologics?
- Alumni Capital and Invus are named as investors in this round.
- What does GenSight Biologics do?
- GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
- Where is GenSight Biologics based and how big is it?
- GenSight Biologics is based in Paris, Ile-de-France, France. Fundz records about 26 employees.
- Who are the decision-makers at GenSight Biologics?
- Fundz holds 4 contacts at GenSight Biologics, including the Chief Technology Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as GenSight Biologics that raised within 45 days of this round, from Fundz verified event records.
- Kodiak Sciences raised $160M (Post-IPO Equity) on December 18, 2025.
- Denali Therapeutics raised $200M (Post-IPO Equity) on December 10, 2025.
- Citius Oncology raised $18M (Funding Round) on December 9, 2025.
- BeyondSpring raised $2M (Funding Round) on November 21, 2025.
- Acasti raised $4M (Funding Round) on October 23, 2025.
- Minerva Neurosciences raised $200M (Funding Round) on October 21, 2025.
Who to call at GenSight Biologics, and when
A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GenSight Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GenSight Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
GenSight Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.